|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current treatment indications and strategies in chronic hepatitis B virus infection显示文摘The optimal approach to the management of several marginal cases with chronic hepatitis B virus (HBV) infection is controversial. Serum HBV DNA and ami-notransferase levels, and the degree of necroinflammation and fibrosis determine the therapeutic decisions. All patients with elevated aminotransferase (> twice the upper limit of normal) and serum HBV DNA above 20 000 IU/mL should be treated. Liver biopsy is important for therapeutic decisions in cases with mild aminotransferase elevations and serum HBV DNA below 20 000 IU/mL. Chronic HBV patients who do not receive treatment should be followed for life. There are seven agents licensed for chronic hepatitis B: standard and pegylated interferon-alpha, lamivudine, adefovir, entecavir, telbivudine and tenofovir. One-year courses with pegylated interferon-alpha induce sustained off-therapy remission in 30%-32% of patients with HBeAg-positive chronic hepatitis B and in a smaller proportion of patients with HBeAg-negative chronic hepatitis B. Oral antivirals achieve initial on-therapy responses in the majority of patients, but are intended as long-term therapies. Viral suppression has favourable effects on patients' outcome and modifies the natural course of the disease. Viral resistance, however, is the major drawback of long-term oral antiviral therapy. Lamivudine monotherapy is associated with the highest and ente-cavir monotherapy with the lowest resistance rate so far. There has been no resistance to tenofovir, but afteronly 18 mo of treatment to date. The optimal first-line anti-HBV therapy with the best long-term cost/benefit ratio remains unclear. If oral antiviral agents are used, compliance should always be ascertained and HBV DNA levels should be regularly tested. | George V Papatheodoridis Spilios Manolakopoulos Athanasios J Archimandritis | 2008 | World Journal of Gastroenterology2008，14，45： | 7 |
| 2 | Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis显示文摘CREB 有约束力的蛋白质(CBP ) 和它的相当或相同事物 p300 是涉及细胞的活动的一个宽数组的各种各样的顺序特定的抄写因素的 transcriptionalco 使活跃之物,例如脱氧核糖核酸修理,房间生长,区别和 apoptosis。Severalstudies 建议了 CBP 和 p300 可能被看作瘤压制 ors,与他们是的突出的角色响应各种各样的刺激的不同基因表示模式的跨 coupling。他们主要经由乙酰化施加行动嘘和另外的规章的蛋白质(例如 p53 ) 。在 CBP/p300 功能的主要悖论是他们似乎能够贡献各种各样的反对细胞的进程。呼吸上皮 tumorigenesis 代表一个范围的多步累积的一个复杂过程基因并且 epigenetic 错误。通过激活和压抑的建筑群的交替的形成的 Transcriptionmodulation 是这些精神错乱的最终的收敛点,并且 CBP/p300 在这相互影响代表关键参加者。因此,他们的分子的行动和相互作用的照明能在呼吸上皮 carcinogenesis 为药理学干预揭示新潜在的目标。 | Michalis V Karamouzis Panagiotis A Konstantinopoulos Athanasios G Papavassiliou | 2007 | Cell Research2007，17，4： | 5 |
| 3 | A case of primary isolated non-Hodgkin’s lymphoma of the esophagus in an immunocompetent patient显示文摘Primary non-Hodgkin’s lymphoma of the esophagus is a rare disease.A case of primary isolated nonHodgkin’s lymphoma of the esophagus in a 77-yearold man without acquired immunodeficiency syndrome is presented.We describe the clinical features and the imaging findings(barium swallow,endoscopic ultrasonography and CT)of a biopsy proven B-cell lymphoma with diffuse transmural involvement of the esophagus wall,which was discovered incidentally.We also briefly review the literature. | Ioannis V Kalogeropoulos Athanasios N Chalazonitis Sofia Tsolaki Fotios Laspas Nikolaos Ptohis Ioannis Neofytou Dimitra Rontogianni | 2009 | World Journal of Gastroenterology2009，15，15： | 5 |
| 4 | Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy显示文摘Pancreatic ductal adenocarcinoma(PDAC)is one of the most lethal diseases,with an average 5-year survival rate of less than 10%.Unfortunately,the majority of patients have unresectable,locally advanced,or metastatic disease at the time of diagnosis.Moreover,traditional treatments such as chemotherapy,surgery,and radiation have not been shown to significantly improve survival.Recently,there has been a swift increase in cancer treatments that incorporate immunotherapybased strategies to target all the stepwise events required for tumor initiation and progression.The results in melanoma,non-small-cell lung cancer and renal cell carcinoma are very encouraging.Unfortunately,the application of checkpoint inhibitors,including anti-CTLA4,anti-PD-1,and anti-PD-L1 antibodies,in pancreatic cancer has been disappointing.Many studies have revealed that the PDAC microenvironment supports tumor growth,promotes metastasis and consists of a physical barrier to drug delivery.Combination therapies hold great promise for enhancing immune responses to achieve a better therapeutic effect.In this review,we provide an outline of why pancreatic cancer is so lethal and of the treatment hurdles that exist.Particular emphasis is given to the role of the tumor microenvironment,and some of the latest and most promising studies on immunotherapy in PDAC are also presented. | Panagiotis Sarantis Evangelos Koustas Adriana Papadimitropoulou Athanasios G Papavassiliou Michalis V Karamouzis | 2020 | World Journal of Gastrointestinal Oncology2020，12，2： | 4 |
| 5 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 6 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 7 | Fecal calprotectin measurement is a marker of shortterm clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease显示文摘AIM To evaluate the utility of fecal calprotectin(FC) in predicting relapse and endoscopic activity during follow-up in an inflammatory bowel disease(IBD) cohort.METHODS All FC measurements that were obtained during a 3-year period from patients with inflammatory bowel disease in clinical remission were identified. Data regarding the short-term(6 mo) course of the disease were extracted from the medical files. Exclusion criteria were defined as:(1) An established flare of the disease at the time of FC measurement,(2) Loss to follow up within 6 mo from baseline FC measurement, and,(3) Insufficient data on file. Statistical analysis was performed to evaluate whether baseline FC measurement could predict the short term clinical relapse and/or the presence of mucosal healing.RESULTS We included 149 [Crohn's disease(CD) = 113, Ulcerative colitis(UC) = 36, male = 77] IBD patients in our study. Within the determined 6-month period post-FC measurement, 47(31.5%) had a disease flare. Among 76 patients who underwent endoscopy, 39(51.3%) had mucosal healing. Baseline FC concentrations were significantly higher in those who had clinical relapse compared to those who remained in remission during follow up(481.0 μg/g, 286.0-600.0 vs 89.0, 36.0-180.8, P < 0.001). The significant predictive value of baseline median with IQR FC for clinical relapse was confirmed by multivariate Cox analysis [HR for 100μg/g: 1.75(95%CI: 1.28-2.39), P = 0.001]. Furthermore, lower FC baseline values significantly correlated to the presence of mucosal healing in endoscopy(69.0 μg/g, 30.0-128.0 vs 481.0, 278.0-600.0, in those with mucosal inflammation, median with IQR, P < 0.001). We were able to extract cut-off values for FC concentration with a high sensitivity and specificity for predicting clinical relapse(261 μg/g with AUC = 0.901, sensitivity 87.2%, specificity 85.3%, P < 0.001) or mucosal healing(174 μg/g with AUC = 0.956, sensitivity 91.9%, specificity 87.2%, P < 0.001). FC was better than CRP in predicting either outcome; nevertheless, having a pathological CRP(> 5 mg/L) in addition to the cutoffs for FC, significantly enhanced the specificity for predicting clinical relapse(95.1% from 85.3%) or endoscopic activity(100% from 87.2%). CONCLUSION Serial FC measurements may be useful in monitoring IBD patients in remission, as FC appears to be a reliable predictor of short-term relapse and endoscopic activity. | Athanasios Kostas Spyros I Siakavellas Charalambos Kosmidis Anna Takou Joanna Nikou Georgios Maropoulos John Vlachogiannakos George V Papatheodoridis Ioannis Papaconstantinou Giorgos Bamias | 2017 | World Journal of Gastroenterology2017，23，41： | 2 |
| 8 | Reaction network of steam reforming of ethanol over Ni-based catalysts显示文摘 | Athanasios F N Xenophon V E | 2004 | J Catal2004，225，2： | 1 |
| 9 | Advanced non-small-cell lung cancer in the elderly显示文摘 | Lambros V Emmanouel S Athanasios K | 2009 | J Clin Oncol2009，5，4： | 1 |
| 10 | A global optimization approach for the linear two-level program显示文摘 | Hoang Tuy Athanasios Migdalas Peter V?rbrand | 1993 | Journal of Global Optimization1993，，1： | 1 |
| 11 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 1 |
| 12 | The power and promise of rewiring the mitogenactivated protein kinase network in prostate cancer therapeutics显示文摘 | ATHANASIOS G MICHALIS V | 2007 | Mol Cancer Ther2007，6，： | 1 |
| 13 | Investigation of triclosan fate and toxicity in continuous-flow activated sludge systems显示文摘 | ATHANASIOS S S ANASTASIOS V P DANIEL M | 2007 | Chemosphere2007，68，2： | 1 |
| 14 | Magnetic resonance angiography isequivalent to X-Ray coronary angiography for the evaluation of coronary arteries in kawasaki disease显示文摘 | Sophie Mavrogeni George Papadopoulos Marouso Douskou Savas Kaklis Ioannis Seimenis Panagiotis Baras Polixeni Nikolaidou Chryssa Bakoula Evangelos Karanasios Athanasios Manginas Dennis V Cokkinos | 2004 | Journal of the American College of Cardiology2004，，4： | 1 |
| 15 | Fair pow- er control using game theory with pricing scheme in cognitive radio networks显示文摘 | Xie X H Yang H L Athanasios V | 2014 | Journal of Communica- tions and Networks2014，16，2： | 1 |
| 16 | Evolutionary coalitional games: design and chMlenges in wireless networks显示文摘 | Manzoor A K Hamidou T and Athanasios V | 2012 | IEEE Wireless Communications2012，19，2： | 1 |
| 17 | Analgesia and an-esthesia for assisted reproductive technologies显示文摘 | Nikos FV Iosifina G Athanasios V | 2009 | Int J Gy-necol Obstes2009，105，3： | 1 |
| 18 | Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms 显示文摘 | Athanasios V Konstantinos F Thomais V | 2008 | J Environ Sci Health C Environ Careinog Ecotoxieol Rev2008，26，： | 1 |
| 19 | Security of the internet of things:perspectives and challenges显示文摘 | Qi Jing Athanasios V Vasilakos | 2014 | Wireless Networks2014，16，6： | 1 |
| 20 | A game-theoretic method of fair resource allocation for cloud computing services 显示文摘 | Wei G Y Athanasios V V Zheng Y | 2010 | The Journal of Supercomputing2010，54，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员